ATE451366T1 - Sulphonamid benzoxazinonderivate. ihre herstellung und verwendung als medikamente - Google Patents

Sulphonamid benzoxazinonderivate. ihre herstellung und verwendung als medikamente

Info

Publication number
ATE451366T1
ATE451366T1 AT04741318T AT04741318T ATE451366T1 AT E451366 T1 ATE451366 T1 AT E451366T1 AT 04741318 T AT04741318 T AT 04741318T AT 04741318 T AT04741318 T AT 04741318T AT E451366 T1 ATE451366 T1 AT E451366T1
Authority
AT
Austria
Prior art keywords
sulphonamide
medications
production
benzoxazinone derivatives
benzoxazinone
Prior art date
Application number
AT04741318T
Other languages
English (en)
Inventor
Jover Antoni Torrens
Prio Josep Mas
Zueras Alberto Dordal
Escasany Maria Angeles Fisas
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of ATE451366T1 publication Critical patent/ATE451366T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04741318T 2003-07-30 2004-07-29 Sulphonamid benzoxazinonderivate. ihre herstellung und verwendung als medikamente ATE451366T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301812A ES2232292B1 (es) 2003-07-30 2003-07-30 Compuestos sulfonamidicos derivados de benzoxazinona, su preparacion y uso como medicamentos.
PCT/EP2004/008507 WO2005014589A1 (en) 2003-07-30 2004-07-29 Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments

Publications (1)

Publication Number Publication Date
ATE451366T1 true ATE451366T1 (de) 2009-12-15

Family

ID=34130545

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04741318T ATE451366T1 (de) 2003-07-30 2004-07-29 Sulphonamid benzoxazinonderivate. ihre herstellung und verwendung als medikamente

Country Status (23)

Country Link
US (1) US20070032482A1 (de)
EP (1) EP1648886B1 (de)
JP (1) JP2007500161A (de)
KR (1) KR20060056355A (de)
CN (1) CN1860114A (de)
AR (1) AR045153A1 (de)
AT (1) ATE451366T1 (de)
AU (1) AU2004263300A1 (de)
BR (1) BRPI0413101A (de)
CA (1) CA2534095A1 (de)
CL (1) CL2004001929A1 (de)
DE (1) DE602004024538D1 (de)
EC (1) ECSP066331A (de)
ES (2) ES2232292B1 (de)
IL (1) IL173004A0 (de)
MX (1) MXPA06001228A (de)
NO (1) NO20060969L (de)
PE (1) PE20050724A1 (de)
PT (1) PT1648886E (de)
RU (1) RU2006105714A (de)
TW (1) TW200510354A (de)
WO (1) WO2005014589A1 (de)
ZA (1) ZA200600426B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1753421B1 (de) * 2004-04-20 2012-08-01 Amgen Inc. Arylsulfonamide und ihre verwendung als hydroxysteroid-dehydrogenase
AR058277A1 (es) 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
GB2435825A (en) * 2006-03-09 2007-09-12 Esteve Labor Dr Benzimidazole-2- & pyrido[d]imidazole-2- sulphonamide derivatives for treatment of disorders mediated via 5-HT6 receptors, eg those related to food intake
EP2053052A1 (de) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Verfahren zur Herstellung von 6-substituiertem Imidazo[2,1-b]thiazol-5-sulfonylhalogenid
ES2821877T3 (es) 2016-07-07 2021-04-28 Bristol Myers Squibb Co Espirolactamas como inhibidores de ROCK
SG11202000833YA (en) * 2017-08-07 2020-02-27 Suven Life Sciences Ltd Fluoropiperidine compounds as pure 5-ht6 receptor antagonists
GB201713780D0 (en) * 2017-08-29 2017-10-11 E-Therapeutics Plc Modulators of hedgehog (Hh) signalling pathway
CN109232599B (zh) * 2018-10-08 2021-04-20 广西中医药大学 具有抗肿瘤活性的o-对三氟甲基苯甲酰基土甘草a及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344945A (en) * 1980-03-10 1982-08-17 Kyowa Hakko Kogyo Co., Ltd. Piperidine derivatives
TW199153B (de) * 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk
AU691829B2 (en) * 1993-07-16 1998-05-28 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
PT889889E (pt) * 1996-03-29 2007-01-31 Duphar Int Res Composto de piperazina e piperidina
SI0906294T1 (en) * 1996-05-29 2003-04-30 Warner-Lambert Company Benzoxazinone dopamine d4 receptor antagonists
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
AU6392701A (en) * 2000-05-12 2001-11-20 Solvay Pharm Bv Piperazine and piperidine compounds

Also Published As

Publication number Publication date
KR20060056355A (ko) 2006-05-24
MXPA06001228A (es) 2006-05-15
ES2232292B1 (es) 2006-11-01
JP2007500161A (ja) 2007-01-11
AU2004263300A1 (en) 2005-02-17
EP1648886B1 (de) 2009-12-09
ECSP066331A (es) 2006-08-30
CA2534095A1 (en) 2005-01-27
IL173004A0 (en) 2006-06-11
AR045153A1 (es) 2005-10-19
ES2338008T3 (es) 2010-05-03
PT1648886E (pt) 2010-03-10
ES2232292A1 (es) 2005-05-16
BRPI0413101A (pt) 2006-10-03
CN1860114A (zh) 2006-11-08
ZA200600426B (en) 2007-03-28
NO20060969L (no) 2006-04-11
DE602004024538D1 (de) 2010-01-21
EP1648886A1 (de) 2006-04-26
PE20050724A1 (es) 2005-11-16
CL2004001929A1 (es) 2005-06-03
TW200510354A (en) 2005-03-16
RU2006105714A (ru) 2007-09-20
WO2005014589A1 (en) 2005-02-17
US20070032482A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
ATE316966T1 (de) Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente
ATE319684T1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
ATE541843T1 (de) 2-acylamino-4-phenylthiazolderivate, ihre herstellung und anwendung als chemokin antagonisten
DE50311318D1 (de) Neue substituierte imidazo-pyridinone und imidazo-pyridazinone, ihre herstellung und ihre verwendung als arzneimittel
ATE539062T1 (de) Bizyklishe verbindung, ihre herstellung und verwendung
ATE469131T1 (de) Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
DE602004028934D1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
DE502005002105D1 (de) 4-benzimidazol-2-yl-pyridazin-3-on-derivative, ihre herstellung und verwendung in arzneimitteln
ATE432701T1 (de) Indol-6-sulfonamid-derivate, ihre herstellung und ihre verwendung als 5-ht-6 modulatoren
DE602006013878D1 (de) Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
DE602004012890D1 (de) Getränke und ihre herstellung
ITMI20030992A1 (it) Additivi perfluoropolieterei.
DE602004010426D1 (de) Mikrobizide zusammensetzungen und ihre verwendung
DE602004021384D1 (de) Indol-5 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE384054T1 (de) Substituierte benzoxazinones und ihre verwendung
DE602004011389D1 (de) Getränke und ihre herstellung
DE60313895D1 (de) 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
ATE533768T1 (de) Imidazol-derivate, ihre herstellung und ihre verwendung
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
DE602005019743D1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
ATE366242T1 (de) 5-substituierte chinazolinonderivate
ATE403649T1 (de) Neue imidazolderivative, deren herstellung und deren verwendung als medikament
ATE451923T1 (de) N-(arylalkyl)-1h-pyrrolopyridin-2-carboxamid- derivate, ihre herstellung und verwendung
ATE542806T1 (de) Diarylmethylpiperazinderivate, deren herstellung und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1648886

Country of ref document: EP

REN Ceased due to non-payment of the annual fee